PMG
BMY icon

ProVise Management Group’s Bristol-Myers Squibb BMY Stock Holding History

ProVise Management Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$247K Sell
4,080
-764
-16% -$44.5K 0.02% 237
2025
Q4 		$261K Buy
4,844
+4
+0.1% +$192 0.02% 230
2025
Q3 		$218K Buy
+4,840
New +$226K 0.02% 239
2025
Q2 		– Sell
-5,195
Closed -$317K – 260
2025
Q1 		$317K Sell
5,195
-89
-2% -$5.19K 0.03% 201
2024
Q4 		$299K Sell
5,284
-2,681
-34% -$150K 0.03% 210
2024
Q3 		$412K Sell
7,965
-454
-5% -$21.3K 0.03% 216
2024
Q2 		$350K Sell
8,419
-5,181
-38% -$232K 0.03% 225
2024
Q1 		$738K Sell
13,600
-1,022
-7% -$52.1K 0.06% 161
2023
Q4 		$750K Sell
14,622
-347
-2% -$18.2K 0.06% 191
2023
Q3 		$869K Sell
14,969
-1,026
-6% -$62.9K 0.08% 182
2023
Q2 		$1.02M Sell
15,995
-14,902
-48% -$999K 0.09% 174
2023
Q1 		$2.14M Buy
30,897
+10,760
+53% +$759K 0.2% 115
2022
Q4 		$1.45M Sell
20,137
-1,036
-5% -$78.1K 0.15% 134
2022
Q3 		$1.5M Buy
21,173
+52
+0.2% +$3.77K 0.17% 127
2022
Q2 		$1.63M Sell
21,121
-2,663
-11% -$203K 0.17% 129
2022
Q1 		$1.74M Sell
23,784
-47,006
-66% -$3.16M 0.16% 134
2021
Q4 		$4.41M Sell
70,790
-42,846
-38% -$2.51M 0.4% 72
2021
Q3 		$6.72M Sell
113,636
-3,129
-3% -$206K 0.67% 45
2021
Q2 		$7.8M Sell
116,765
-2,796
-2% -$182K 0.8% 32
2021
Q1 		$7.55M Sell
119,561
-556
-0.5% -$34.6K 0.81% 30
2020
Q4 		$7.45M Buy
120,117
+1,505
+1% +$92.5K 0.86% 31
2020
Q3 		$7.15M Buy
118,612
+321
+0.3% +$19.3K 0.96% 25
2020
Q2 		$6.96M Sell
118,291
-3,383
-3% -$202K 1% 26
2020
Q1 		$6.78M Buy
121,674
+9,196
+8% +$562K 1.14% 21
2019
Q4 		$7.22M Buy
112,478
+54,952
+96% +$3.15M 0.89% 33
2019
Q3 		$2.92M Buy
57,526
+41,372
+256% +$1.94M 0.39% 76
2019
Q2 		$733K Buy
16,154
+301
+2% +$14K 0.1% 165
2019
Q1 		$756K Sell
15,853
-4,881
-24% -$243K 0.11% 157
2018
Q4 		$1.08M Buy
20,734
+4,212
+25% +$226K 0.17% 134
2018
Q3 		$1.03M Sell
16,522
-199
-1% -$11.8K 0.14% 148
2018
Q2 		$925 Buy
16,721
+501
+3% +$27.1K 0.07% 170
2018
Q1 		$1.03M Buy
16,220
+1,040
+7% +$66.9K 0.15% 143
2017
Q4 		$930K Sell
15,180
-1,309
-8% -$81.9K 0.13% 147
2017
Q3 		$1.05M Buy
16,489
+733
+5% +$42.8K 0.15% 148
2017
Q2 		$877K Buy
15,756
+4,381
+39% +$238K 0.13% 151
2017
Q1 		$619K Sell
11,375
-42
-0.4% -$2.3K 0.1% 188
2016
Q4 		$667K Sell
11,417
-575
-5% -$31.4K 0.11% 184
2016
Q3 		$646K Sell
11,992
-18,600
-61% -$1.19M 0.11% 183
2016
Q2 		$2.25M Buy
30,592
+200
+0.7% +$14.1K 0.41% 75
2016
Q1 		$1.94M Sell
30,392
-650
-2% -$41K 0.4% 75
2015
Q4 		$2.13M Buy
31,042
+292
+0.9% +$19.3K 0.45% 69
2015
Q3 		$1.82M Buy
30,750
+700
+2% +$44.4K 0.42% 75
2015
Q2 		$2M Buy
30,050
+3,450
+13% +$227K 0.43% 74
2015
Q1 		$1.72M Hold
26,600
– – 0.36% 84
2014
Q4 		$1.57M Hold
26,600
– – 0.34% 94
2014
Q3 		$1.36M Sell
26,600
-6,999
-21% -$350K 0.3% 103
2014
Q2 		$1.63M Buy
33,599
+3,262
+11% +$161K 0.35% 88
2014
Q1 		$1.58M Buy
30,337
+935
+3% +$49.8K 0.38% 76
2013
Q4 		$1.56M Sell
29,402
-1,402
-5% -$71.4K 0.4% 77
2013
Q3 		$1.43M Buy
30,804
+85
+0.3% +$3.73K 0.4% 69
2013
Q2 		$1.37M Buy
+30,719
New +$1.33M 0.41% 69

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProVise Management Group's BMY Position: Q1 2026 in Review

ProVise Management Group reduced its Bristol-Myers Squibb (BMY) stake by 16% in Q1 2026, selling an estimated $44.5K and leaving 4,080 shares worth $247K. The position accounts for 0.02% of the portfolio, ranked #237.

ProVise Management Group first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $7.8M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • ProVise Management Group held 4,080 shares of Bristol-Myers Squibb worth $247K as of Q1 2026.
  • ProVise Management Group sold 764 Bristol-Myers Squibb shares in Q1 2026, an estimated $44.5K.
  • Bristol-Myers Squibb made up 0.02% of ProVise Management Group's portfolio in Q1 2026, its #237 holding.
  • ProVise Management Group first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • ProVise Management Group's Bristol-Myers Squibb position peaked at $7.8M in Q2 2021.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on ProVise Management Group's 13F filing for Q1 2026, filed 7 May 2026.